Clinical Trial Update: Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout [Phase 2, Phase 3]

View source ↗

Summary

Phase 2b/3 trial evaluating ABP-671, a URAT1 inhibitor, for gout has completed according to the update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout

Drugs mentioned

• ABP-671

Snippet

Sponsor: Atom Therapeutics Co., Ltd | Conditions: Gout | Phase 2, Phase 3 | Status: COMPLETED